Antiretroviral drugs to prevent breastfeeding HIV transmission

Antiviral Therapy

Volumn 15, Issue 4, 2010, Pages 537-553

  Mofenson, Lynne M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; STAVUDINE; TENOFOVIR; ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABNORMAL LABORATORY RESULT; BLOOD TOXICITY; BREAST FEEDING; BREAST MILK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MORTALITY; NEUTROPENIA; OVERALL SURVIVAL; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; CHEMOPROPHYLAXIS; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; LACTATION; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSMISSION; VIROLOGY;

ANTI-HIV AGENTS; BREAST FEEDING; CHEMOPREVENTION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LACTATION; MILK, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77956851018     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1574     Document Type: Review

References (51)

1. UNAIDS, WHO. AIDS epidemic update: November 2009. Geneva: UNAIDS, WHO 2009. (Updated 25 November 2009. Accessed 4 May 2010.) Available from http://data.unaids.org/pub/Report/2009/2009-epidemic-update-en.pdf
2. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107-1116.
3. Kuhn L, Sinkala M, Kankasa C, et al. High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission. PLoS ONE 2007; 2:e1363.
4. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981.
5. UNICEF. Children and HIV and AIDS. (Updated 10 December 2009. Accessed 26 November 2009.) Available from http://www.unicef.org/aids/index.php
6. WHO. Towards universal access: scaling up priority HIV/ AIDS interventions in the health care sector: progress report 2009. Geneva: WHO 2009. (Updated 3 November 2009. Accessed 4 May 2010.) Available from http://data.unaids. org/pub/Report/2009/20090930-tuapr-2009-en.pdf
7. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings; towards universal access: recommendations for a public health approach - 2006 version. Geneva: WHO 2006.
8. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents - November 2009. Geneva: WHO 2009. (Updated 23 February 2010. Accessed 4 May 2010.) Available from http://www.who.int/hiv/pub/arv/rapid- advice-art.pdf
9. WHO. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants - November 2009. Geneva: WHO 2009. (Updated 23 March 2010. Accessed 4 May 2010.) Available from http://www.who.int/hiv/pub/mtct/rapid-advice-mtct.pdf
10. Severe P, Pape J, Fitzgerald DW, et al. A randomized clinical trial of early versus standard antiretroviral therapy for HIVinfected patients with a CD4 T cell count of 200-350 cells/ml (CIPRAHT001). Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2009, San Francisco, CA, USA. Abstract H-1230c.
11. Mmiro FA, Aizire J, Mwatha AK, et al. Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr 2009; 52:32-39.
12. Becquet R, Ekouevi DK, Arrive E, et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009; 49:1936-1945.
13. Mofenson LM, Taha TE, Qing L, et al. Infant extended antiretroviral (ARV) prophylaxis is effective in preventing postnatal mother to child HIV transmission (MTCT) at all maternal CD4 vounts. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 12-22 July 2009, Capetown, South Africa. Abstract TuPEC053.
14. Chasela C, Chen YQ, Fiscus S, et al. Risk factors for late postnatal transmission of human immunodeficiency virus type 1 in sub-Saharan Africa. Pediatr Infect Dis J 2008; 27:251-256.
15. The Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data metaanalysis. J Infect Dis 2004; 189:2154-2166.
16. Kuhn L, Aldrovandi G, Sinkala M, et al. Potential impact of new World Health Organization criteria for antiretroviral treatment for prevention of mother to child HIV transmission. AIDS 2010; 24:1374-1377.
17. Brown ER, Otieno P, Mbori-Ngacha DA, et al. Comparison of CD4 cell count, viral load and other markers for prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis 2009; 199:1292-1300.
18. Dugan K, Carter R, Toro P, et al. Comparing clinical and immunologic criteria for determining HAART eligibility among HIV-infected pregnant and postpartum women in low resource settings. 1st International Workshop on HIV Pediatrics. 17-18 July 2009, Capetown, South Africa. Abstract O15.
19. Ekouevi DK, Inwoley A, Tonwe-Gold B, et al. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses 2007; 23:1469-1474.
20. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 2006; 296:794-805.
21. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48:315-323.
22. Vyankandondera J, Luchters S, Hassink E, et al. SIMBA - Stopping Infection from Mother to Child via Breastfeeding in Africa. 3rd International AIDS Society Conference on HIV Pathogenesis. 24-27 July 2003, Paris, France. Abstract LB07.
23. Six Week Extended-Dose Nevirapine (SWEN) Study Team. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008; 372:300-313.
24. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008; 359:119-129.
25. Chasela CS, Hudgens MG, Jaimeson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-2281.
26. Marazzi CM, Germano P, Liotta G, et al. Implementing antiretroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings. Eur J Pediatr 2007; 166:1305-1307.
27. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21 Suppl 4:S65-S71.
28. Thomas T, Masaba R, Ndivo R, et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu Breastfeeding Study, Kisumu, Kenya, 2003-2007. 14th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 45aLB.
29. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the MITRA PLUS Study. J Acquir Immune Defic Syndr 2009; 52:406-416.
30. Peltier CA, Ndayisaba GF, Lepage P, et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother to child infection in Rwanda. AIDS 2009; 23:2415-2423.
31. de Vincenzi I, the Kesho Bora Study Group. Triple-antiretroviral prophylaxis during pregnancy and breastfeeding compared to short-ARV prophylaxis to prevent mother-to-child transmission of HIV-1: the Kesho Bora randomized controlled clinical trial in five sites in Burkina Faso, Kenya and South Africa. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract LBPE C01.
32. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N Engl J Med 2010; 362:2282-2294.
33. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. Lancet 2000; 355:451-455.
34. Maclean CC, Stringer JSA. Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breastfeeding. J Acquir Immune Defic Syndr 2005; 38:570-577.
35. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire. AIDS 2008; 22:1815-1820.
36. Van der Merwe K, Chersich M, Black V, et al. The impact of in-utero antiretroviral therapy (ART) exposure on infant outcomes in Johannesburg, South Africa. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. 19-22 July 2009, Cape Town, South Africa. Abstract WePE B262.
37. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026. (Pubitemid 46684333)
38. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-615. (Pubitemid 46303654)
39. Moorthy A, Gupta A, Bhosale R. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 2009; 4:e4096.
40. Lidstrom J, Li Q, Hoover DR, et al. Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. AIDS 2010; 24:381-386.
41. Zeh C, Weidle P, Nafisa L, et al. Emergence of HIV-1 drug resistance among breastfeeding infants born to HIV-infected mothers taking antiretrovirals for prevention of mother-to-child transmission of HIV: the Kisumu Breastfeeding Study, Kenya. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 84LB.
42. Lidstrom J, Kumwenda N, Kafulafula G, et al. Antiretroviral treatment of HIV-infected women can induce multi-class drug resistance in their breastfeeding infants. Antivir Ther 2009; 14 Suppl 1:A158.
43. Lidstrom J, Guay L, Musoke P, et al. Multi-class drug resistance arises frequently in HIV-infected breastfeeding infants whose mothers initiate HAART postpartum. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 920.
44. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-1176.
45. Colebunders R, Hodossy B, Burger D, et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005; 19:1912-1915.
46. Kuhn L, Aldrovandi GM, Sinkala M, et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 2008; 359:130-141.
47. Kafulafula G, Hoover D, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6-13.
48. Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to hiv-infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2010; 53:28-35.
49. Thomas T, Masaba R, van Eijk A, et al. Rates of diarrhoea associated with early weaning among infants in Kisumu, Kenya. 14th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 774.
50. Creek TL, Kim A, Lu L, et al. Hospitalization and mortality among primarily nonbreastfed children during a large outbreak of diarrhea and malnutrition in Botswana, 2006. J Acquir Immune Defic Syndr 2010; 53:14-19.
51. WHO. Rapid advice: infant feeding in the context of HIV - November 2009. Geneva: WHO 2009. (Updated 30 November 2009. Accessed 4 May 2010.) Available from http://www.who.int/hiv/pub/paediatric/advice/en